Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

BACKGROUND: Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. METHODS: In this phase 2 trial, patients with locally advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Chuanliang, Chen, Yu, Luo, Zhiguo, Zou, Zhengyun, Jiang, Yu, Pan, Hongming, Fan, Qingxia, Zhao, Jianfu, Xu, Qing, Jiang, Renbing, Wang, Xuan, Ma, Taiyang, Guo, Zhen, Si, Lu, Chi, Zhihong, Sheng, Xinan, Dou, Yiwei, Tan, Qian, Wu, Di, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901108/
https://www.ncbi.nlm.nih.gov/pubmed/36747118
http://dx.doi.org/10.1186/s12885-022-10473-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901108/
https://www.ncbi.nlm.nih.gov/pubmed/36747118
http://dx.doi.org/10.1186/s12885-022-10473-y

Ejemplares similares